Ledger.Open graph →
SEC Form D · filed December 27, 2023

Spyre Therapeutics, Inc

Offering
$180.0M
Sold
$180.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Waltham, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Tomas J. Kiselak · Austin, TXDirectorPeter J. Harwin · Austin, TXDirectorCameron Turtle · Austin, TXExec · DirectorScott Burrows · Calgary, Alberta, CanadaExecLaurie J. Stelzer · Waltham, MADirectorRussell J. Cox · Austin, TXDirectorAlison J. Lawton · Austin, TXDirectorMichael J. Henderson · Austin, TXDirectorHeidy King-Jones · Waltham, MAExecJeffrey W. Albers · Cambridge, MADirectorCameron Turtle · Austin, TXExec · DirectorTomas J. Kiselak · Austin, TXDirectorScott Burrows · Waltham, MAExecLaurie J. Stelzer · Waltham, MADirectorRussell J. Cox · Austin, TXDirectorPeter J. Harwin · Austin, TXDirectorAlison J. Lawton · Austin, TXDirectorMichael J. Henderson · Austin, TXDirectorHeidy King-Jones · Waltham, MAExecJeffrey W. Albers · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗